STOCK TITAN
  1. Home
  2. News
  3. CPRX

Catalyst Pharmaceuticals Inc - CPRX STOCK NEWS

Welcome to our dedicated news page for Catalyst Pharmaceuticals (Ticker: CPRX), a resource for investors and traders seeking the latest updates and insights on Catalyst Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Catalyst Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Catalyst Pharmaceuticals's position in the market.

News
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. endorses the inaugural Lambert-Eaton myasthenic syndrome Awareness Day, marking a significant milestone for the LEMS community. The event, observed annually on March 30th, commemorates the groundbreaking research of Dr. Lambert and Dr. Eaton, enhancing understanding and treatment of this rare disorder. Catalyst emphasizes the importance of raising awareness for rare diseases, aiming to improve support and care for affected individuals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
none
-
News
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. announced CEO Richard J. Daly's participation in the 2024 Cantor Virtual Muscular Dystrophy Symposium. The event will take place on April 2-3, 2024, at 3:10 PM ET. The presentation will be available on the Company's website with a replay for 14 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.3%
Tags
conferences
-
News
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. announces the U.S. commercial launch of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy patients aged two years and older. The drug offers a promising alternative to traditional corticosteroid treatments, aiming to improve patient quality of life with reduced side effects. Catalyst Pathways® program supports patient access and affordability, emphasizing the company's commitment to providing comprehensive care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
none
News
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. CEO Richard J. Daly and management team to participate in Barclays 26th Annual Global Healthcare Conference in Miami. The event includes 1x1 meetings and a fireside discussion on March 12, 2024, with a live webcast and replay available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
conferences
-
News
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. reported strong financial results for the fourth quarter and full year 2023, with record total revenues of $398.2 million, an 85.9% increase compared to 2022. The company achieved record net product revenues and reported GAAP net income of $71.4 million. The FDA approval of AGAMREE for Duchenne muscular dystrophy and the upcoming commercial launch in Q1 2024 are key highlights. Catalyst provided a full-year 2024 revenue guidance of $455 million to $475 million and announced key executive appointments and strategic collaborations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.1%
Tags
earnings
-
News
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. (CPRX) announces an upcoming poster presentation at the American Academy of Neurology Annual Meeting showcasing Firdapse data for LEMS patients. The company continues its commitment to developing innovative treatments for rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
conferences
News
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
Rhea-AI Summary
Santhera's study on Vamorolone in Duchenne Muscular Dystrophy patients showed positive long-term efficacy and safety results, supporting the use of Vamorolone. The study demonstrated that Vamorolone was well-tolerated and effective in improving motor outcomes over 48 weeks, with potential benefits in growth and bone health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
News
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. announces a conference call and webcast to discuss its fourth quarter and full-year 2023 financial results. The event will take place on February 29, 2024, at 8:30 AM ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
conferences earnings
-
News
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. (CPRX) closes underwritten public offering, selling 10,000,000 shares at $15.00 per share, generating approximately $140.1 million in net proceeds. The company plans to use the funds for potential acquisition of new product candidates and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
offering
News
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share, totaling gross proceeds of $150,000,000 before deducting underwriting discounts and expenses. Catalyst also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock offered in the public offering. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.85%
Tags
offering
Stock CPRX logo
Catalyst Pharmaceuticals Inc

Nasdaq:CPRX

CPRX Rankings

#1929 Ranked by Market Cap
#2926 Ranked by Stock Gains
N/A Ranked by Dividends

CPRX Stock Data

1.80B
101.40M
6.21%
73.15%
5.14%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Coral Gables

About CPRX

catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso